Previous 10 | Next 10 |
Vyant Bio press release ( NASDAQ: VYNT ): Q3 GAAP EPS of -$0.62 beats by $0.08 . Revenue of $0.15M (-42.3% Y/Y). Shares -2.63% PM. For further details see: Vyant Bio GAAP EPS of -$0.62 beats by $0.08, revenue of $0.15M
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoP harm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash payment Delivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou ...
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company rei...
Vyant Bio ( NASDAQ: VYNT ) said Thursday it will sell its unit vivoPharm in Hershey, Pennsylvania to contract research organization Reaction Biology for $5.5M in cash. Shares of Vyant ( VYNT ) edged 4.6% higher on Thursday. Reaction will retain U.S. p...
~ Reaction Biology Acquire s the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction E xpands Reaction Biology’s Capabilities to P rovide Customers with S olut...
Vyant Bio ( NASDAQ: VYNT ) is trading 1% lower after the company will effect a 1-for-5 reverse stock split of its outstanding common stock. The company will become effective for trading purposes as of the commencement of trading on Wednesday, November 2. Vyant...
CHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
P latform and P oster Presentation s on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWI...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...